[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,80,114,137,170,193,224],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100590173","using-community-health-workers-to-support-rural-care-partners-of-seriously-ill-older-veterans-100590173",false,"NCT06963970","Using Community Health Workers to Support Rural Care Partners of Seriously Ill Older Veterans","PATH","Inclusion Criteria:\n\nCare Partner Inclusion Criteria\n\n* A relative, friend, or partner (18 years of age) with whom Veteran patient has a personal relationship who assists Veteran regularly with care and\u002For care coordination as defined under \"Veterans\" below\n* Residing in a rural area based on RUCC or Rural-Urban Continuum Codes83\n* Must be enrolled in CSP Program of General Caregiver Support Services\n* Can live with or separately from the Veteran; able to communicate in English by phone\n\nVeteran Inclusion Criteria\n\n* Receiving care at Durham, Asheville, and Richmond VA Health Systems (e.g., at least 2 outpatient visits in past year; has a primary provider) and residing in a rural area.\n* Diagnosed with congestive heart failure, chronic obstructive pulmonary disease, cancer, dementia, or end-stage renal disease.\n* Requires assistance with at least one ADL (i.e., walking, feeding, toileting, transferring, bathing, or dressing) or IADL (i.e., transport, medication, financial management, shopping, or meal preparation)\n* 50 years old or older and able to communicate in English by phone (for assessments)\n\nExclusion Criteria:\n\nVeteran Exclusion Criteria\n\n* Flag or social work note indicating suspected Caregiver abuse.\n* Unable to communicate in English by phone for assessments.",true,"ALL","18 Years",{"count":20,"type":21},480,"ESTIMATED","INTERVENTIONAL",[24],"NA","The investigators aim to support care partner's well-being and satisfaction with VA care and decrease their work burden by offering extra support from a trained Community Health Worker who will help connect the care partner to helpful resources in their communities and in the VA. The investigators also hope to help Veterans well-being and satisfaction with VA care by supporting their care partner more sufficiently allowing the care partner to focus on caregiving tasks.",[27,28,29,30],"Dementia","Cancer","Renal Disease","Obstructive Pulmonary Disease","NOT_YET_RECRUITING","2026-06-16",{"date":34,"type":35},"2026-06-17","ACTUAL",{"date":37,"type":21},"2026-09-01",{"date":39,"type":21},"2028-09-30",{"name":41,"class":42},"VA Office of Research and Development","FED",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100451089","cooperative-assessment-of-late-effects-for-scd-curative-therapies-100451089","NCT05153967","Cooperative Assessment of Late Effects for SCD Curative Therapies","U01 Cooperative Assessment of Late Effects for Sickle Cell Disease Curative Therapies","COALESCE","Inclusion Criteria\n\n* Confirmed laboratory diagnosis of SCD\n* Ability to give informed consent\n* Ability to provide pre- and post-curative therapy data\n* Treated with either one HSCT or with standard disease-modifying therapy\n\nExclusion Criteria\n\n•History of non-compliance","4 Years","65 Years",{"count":55,"type":21},750,"OBSERVATIONAL","Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with \\>99% of those born in high resource settings, including the United States, France, and England, now surviving to 18 years of age. However, the life expectancy of adults with SCD is severely shortened. Dysfunction of the heart, lung, and kidney is directly associated with decreased life expectancy. With the variety of curative therapies that are now available for SCD, long-term health outcomes studies are time-sensitive. As of now, efforts to determine long-term health outcomes following curative therapies for SCD have been limited. Though curative therapies initially should provide a cure for symptoms of SCD, there is the risk of late health outcomes to consider. Defining health outcomes following curative therapy is essential to improve personalized decision-making when considering curative versus disease-modifying therapeutic options. The primary goal of this study is to determine whether curative therapies for individuals with SCD will result in improved or worsening heart, lung, and kidney damage when compared to individuals with SCD receiving standard therapy. The investigators will also explore whether certain genes are associated with a good or bad outcome after curative therapy for SCD.",[59,60,29,61],"Sickle Cell Disease","Pulmonary Disease","Heart Disease",[63,64,65,66,67],"Myeloablative Autologous Gene Editing","Myeloablative Autologous Gene Therapy","Myeloablative allo-HSCT","Nonmyeloablative allo-HSCT","Disease-Modifying Therapy","RECRUITING","2026-01-28",{"date":71,"type":35},"2026-01-30",{"date":73,"type":35},"2022-07-12",{"date":75,"type":21},"2027-02",{"name":77,"class":78},"Vanderbilt University Medical Center","OTHER",5,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":79},"100557309","planning-operative-strategy-using-a-digital-renal-artery-clamping-tool-100557309","NCT06536439","Planning Operative Strategy Using a Digital Renal Artery Clamping Tool","Planning Operative Strategy Using a Digital Renal Artery Clamping Tool: a Randomized Controlled Trial Evaluating the DIPLANN 3D Model for Selective Arterial Clamping During Robot-Assisted Partial Nephrectomy","PODRACING","Inclusion Criteria:\n\n* aged 18 years or above\n* cT1-2 N0 M0 renal mass\n* planned to undergo RAPN\n* multiphase CT scan with arterial phase available\n* voluntary given and written informed consent\n* sufficient in at least one of the study languages: Dutch, English, French\n\nFor the primary objective, SC needs to be deemed possible either according to the DIPLANN-tool in combination with conventional CT imaging or according to conventional CT imaging only, as assessed by an independent surgeon (between inclusion and randomization) who will not be involved in the RAPN surgical procedure, in order to be included in the analysis set. On the DIPLANN tool, SC is deemed feasible if \\>= 90% tumor ischemia and \\\u003C= 70% renal parenchyma ischemia can be achieved. If these criteria are met, but it is technically or anatomically not feasible according to the independent surgeon to perform SC, he can deviate from these criteria and thus claim SC is not deemed possible. The results for the total population (patients in which SC is deemed possible AND impossible pre-operatively by an independent surgeon) will also be analyzed as a secondary objective.\n\nExclusion Criteria:\n\n* \\> 3 ipsilateral renal masses\n* women who are pregnant or breastfeeding\n* previous renal surgery that is expected to complicate renal cancer surgery\n* cT ≥ 3\n* planned off-clamp resection\n* cognitive disorder which impedes with completing study questionnaires",{"count":89,"type":21},235,[24],"A proposed new tool ('DIPLANN-tool' - Digital Planning in Nephrectomy) for predicting kidney perfusion zones on a segmented 3D model during robot-assisted partial nephrectomy (RAPN) for localized renal cancer demonstrated high accuracy when planning selective clamping (SC) for RAPN. However, the tool's clinical added value still needs to be confirmed. Therefore, a randomized controlled trial using a study and control group is the preferred study design.\n\nExperimental group: the use of the DIPLANN-tool + conventional computed tomography (CT) imaging for preoperative planning and perioperative guidance during RAPN.\n\nControl group: the use of only conventional CT imaging for preoperative planning and perioperative guidance during RAPN (= current standard of care).\n\nThe primary endpoint is planning and performing as planned a SC strategy. Secondary endpoints include patients' health, patients' insight and surgeons' benefits.",[93,94,95,96,97,29],"Kidney Cancer","Kidney Neoplasms","Kidney Diseases","Renal Cancer","Renal Cell Carcinoma",[93,97,99,100,101,102,103,104],"Minimally Invasive Surgery","Robot-Assisted Surgery","Robot-Assisted Partial Nephrectomy","RAPN","3D","Perfusion Zone","2025-03-26",{"date":107,"type":35},"2025-04-01",{"date":109,"type":35},"2024-06-27",{"date":111,"type":21},"2027-01-01",{"name":113,"class":78},"University Hospital, Ghent",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":43},"100544167","systemic-lupus-erythematosus-and-chlordecone-impregnation-in-martinique-100544167","NCT06365359","Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique","LUNEK","Inclusion Criteria:\n\n* Patients with systemic lupus erythematosus according to the ACR 1997 or ACR\u002FEULAR 2019 criteria,\n* Present in the active line of the internal medicine department of the Martinique University Hospital since 2005,\n* Whose illness has been progressing for at least 3 years,\n* Living in Martinique or Guadeloupe for at least 1 year,\n* Patients who have given their free, informed and written consent.\n\nExclusion Criteria:\n\n* Patients for whom kidney disease cannot be authenticated or ruled out (refusal, contraindication or impossibility of renal biopsy),\n* Patients without social security coverage,\n* Current legal protection,\n* Patients who have not given their consent to the use of their data,\n* Pregnant or breastfeeding women.",{"count":122,"type":21},200,"Chlordecone, an organochlorine pesticide, was widely used on banana farms in the French West Indies. Studies by Inserm and health authorities have confirmed the contamination of the food chain and the majority of the population of the French West Indies by chlordecone.\n\nEpidemiological studies conducted in the French West Indies have shown that exposure to chlordecone at the levels observed is associated with an increased risk of developing several diseases, including premature birth and prostate cancer. Many of the adverse effects associated with chlordecone could be explained by its estrogenic hormonal properties, and systemic lupus erythematosus (SLE) is an autoimmune disease whose sensitivity to estrogen is well known and is reflected by 1) its clear predominance in women, 2) its predominance in women of childbearing age, 3) its risk of exacerbation in the event of pregnancy.\n\nChlordecone has the potential to modify the activity of SLE through mechanisms other than its pro-estrogenic effects. In rats, chlordecone was observed to induce alterations such as a reduction in lymphocyte count, thymic atrophy, and a decrease in splenic germinal centers and NK cells.\n\nIn a mouse model of systemic lupus erythematosus (SLE), exposure to chlordecone results in increased production of immune complexes and anti-DNA antibodies, which are markers of disease activity and monitoring.\n\nChlordecone also has a cellular effect that reduces the apoptosis of potentially auto-reactive lymphocytes and stimulates the production of GM-CSF, IL-2, TNF-alpha, and IFN-gamma. The latter is central to the pathophysiology of SLE. While experimental studies suggest a potential impact of chlordecone on SLE, no human studies have been conducted to date, and the chlordecone impregnation of lupus patients in Martinique remains unknown.\n\nThe most serious and feared complication of SLE is kidney damage. Kidney damage from the disease and the necessary immunosuppressive treatments can lead to significant morbidity and mortality, including death and end-stage chronic renal failure. Therefore, it is important to manage the disease carefully. Suspected lupus nephritis is confirmed by a renal biopsy, which allows for formal diagnosis and categorization into several classes. Suspected cases are identified by a proteinuria to creatininuria ratio greater than 0.5 g\u002Fg (or 24-hour proteinuria greater than 0.5g).\n\nThe objective of this project is to determine whether there is a positive association between lupus nephritis occurrence in patients followed by the internal medicine department of the Martinique University Hospital and organochlorine pesticide chlordecone impregnation.",[125,29],"Systemic Lupus Erythematosus",[125,127,128,29],"Chlordecone impregnation","Organochlorine pesticide (chlordecone, p,p'-DDE, βHCH, γHCH, PCB 153)",{"date":130,"type":35},"2025-03-31",{"date":132,"type":35},"2025-01-02",{"date":134,"type":21},"2026-09-02",{"name":136,"class":78},"University Hospital Center of Martinique",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":146,"conditions":147,"keywords":156,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":43},"100571233","variation-in-drug-interactions-in-people-with-hiv-plwh-aged-60-years-and-older-100571233","NCT06717581","Variation in Drug Interactions in People With HIV (PLWH) Aged 60 Years and Older.","Variation in Drug Interactions in People With HIV (PLWH) Aged 60 Years and Older on Stable Antiretroviral Therapy Making a Switch to Bictegravir\u002FTenofovir Alafenamide\u002FEmtricitabine","Inclusion Criteria:\n\n* Age \\> 60 years\n* Non-infectious comorbidities receiving drug therapy\n* Receiving BIC\u002FTAF\u002FFTC therapy at the time of of enrollment\n\nExclusion Criteria:\n\n* Genotypic resistance testing that present or past evidence of viral resistance to the integrase inhibitor class, to emtricitabine or to tenofovir\n* Severe acute infectious disease",{"count":145,"type":21},50,"Several cohort studies have recently shown a significant increase in the mean age of PLWH ( People Living With HIV) and in the prevalence of people in advanced age in the various cohorts, as a result of the marked increase in the mean life expectancy of these people achieved by modern antiretroviral combination therapies.\n\nHowever, the high prevalence of comorbidities exposes PLWH in old age to the need to take multiple drug treatments in addition to antiretroviral therapy, with the gradually increasing risk of unfavorable pharmacokinetic interactions between antiretroviral drugs and drugs taken to treat the comorbidities.\n\nThis project consists of an observational, cohort, retrospective, single-center study and aims to evaluate the variation in the number and type of clinically significant drug interactions between antiretroviral therapy and concomitant therapies in PLWH aged \\>60 years on stable antiretroviral therapy who, for any reason at the Clinician's discretion, have made a switch from ongoing antiretroviral therapy to the bictegravir\u002Femtricitabine\u002Ftenofovir alafenamide regimen.",[148,149,150,151,152,153,29,154,155],"HIV Infections","Drug Interaction","Elderly Infection","Comorbidities and Coexisting Conditions","Cardiovascular Diseases","Metabolic Disease","Osteoporosis Risk","Neoplasms",[157,158,159,160],"HIV","Drug Interactions","Retrovirus","Comorbidities","2024-12-01",{"date":163,"type":35},"2024-12-05",{"date":165,"type":35},"2024-10-11",{"date":167,"type":21},"2025-10-11",{"name":169,"class":78},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":43},"100352491","evaluation-of-a-screening-strategy-of-fabry-disease-in-patient-with-renal-biopsy-100352491","NCT03869554","Evaluation of a Screening Strategy of Fabry Disease in Patient With Renal Biopsy","Evaluation of a Screening Strategy of Fabry Disease in Patient With Renal Biopsy: Histo-Fab Study","HISTOFAB","Inclusion Criteria:\n\n* Adult patient (\\> 18 years old)\n* Obtaining consent to participate in the study\n* Patients whose clinical presentation meets at least one of the following criteria:\n\n  * Undetermined nephropathy despite renal biopsy,\n  * Nephroangiosclerosis as the predominant lesion\n  * Chronic tubulointerstitial nephropathy,\n  * Glomerulosclerosis,\n  * Segmental and focal hyalinosis.\n  * Optically normal kidney or seat of minimal lesions\n\nExclusion Criteria:\n\n* Patient who has already been screened for Fabry Disease\n* At least one of the following criteria:\n\n  * Nephrotic syndrome and\u002For Glomerular nephropathy\n  * Histological diagnosis of certain nephropathies (specific kidney lesions)",{"count":179,"type":21},100,[24],"Fabry disease is genetic X linked disease, with annual incidence of 1 in 100,000 that is certainly underestimate the true prevalence of the disease.\n\nRenal biopsy in some patients does not allow determining the etiology of nephropathy. It is why investigators would like to evaluate the screening of Fabry patients from renal biopsy in patient with idiopathic nephropathy.\n\nInvestigator hypothesize to detect one or more cases of patients with Fabry disease in local idiopathic nephropathy population with renal biopsy.\n\nThat would allow reviewing and optimizing the target screening for Fabry Disease. The purpose would be to detect Fabry disease systematically in patients presenting a nephropathy of undetermined etiology in spite of the renal biopsy or presenting nonspecific histological characteristics.\n\nIn Fabry disease with renal impairment, proteinuria is the first sign, usually occurring in the second decade. The evolution is progressively towards end-stage renal failure during the fourth decade. The presence of renal impairment is globally associated with a poor prognosis.\n\nRenal histology can be used to diagnose Fabry disease by revealing sphingolipid deposits identified by optical microscopy in the form of vacuoles in podocytes, distal tubule epithelial cells or in the media of the distal tubules. vascular walls. Resin inclusion with Toluidine blue staining is the staining of choice for visualizing lipid inclusions. However, this staining is not used as a first intention in routine. On the paraffin-fixed tissues, the vacuoles are less visible because they dissolve.\n\nThus, the renal histological analysis sometimes reveals only non-specific damage to the various structures of the kidney and may not allow identification of very evocative inclusions. Under the effect of oxidative stress induced by sphingolipid deposits, lesions of tubulo-interstitial fibrosis settle quite early. At the level of the glomerulus, glycosphingolipids lead to the production of angiotensin II and TGF-β leading to an excess production of constituents of the glomerular basement membrane inducing its thickening and glomerulosclerosis. Arteries of all sizes are also the seat of intimal thickening and media accelerating the process of intrarenal ischemia. These lesions, which may appear isolated or synchronous, and nonspecific, are sometimes in the foreground and do not point in the first line to the etiological diagnosis of Fabry disease.\n\nAlso, among the patients presenting a nephropathy of undetermined etiology in spite of the renal biopsy or presenting nonspecific histological characteristics, investigator propose to systematically detect the Fabry disease. Screening will be done in a selected population of renal biopsy patients using the dried blood spot kits.",[29],"2024-06-10",{"date":185,"type":35},"2024-06-11",{"date":187,"type":35},"2020-02-03",{"date":189,"type":21},"2025-08-02",{"name":191,"class":192},"University Hospital, Angers","OTHER_GOV",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":204,"conditions":205,"keywords":212,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":223},"100303086","prospective-urban-rural-epidemiology-study-100303086","NCT03225586","Prospective Urban Rural Epidemiology Study","PURE","Inclusion Criteria:\n\n* consenting adults between 35-70 years of age\n\nExclusion Criteria:\n\n* none","35 Years","70 Years",{"count":203,"type":21},200000,"To examine the impact of health determinants at the individual (e.g. health related behaviors) and societal level (e.g. environmental factors, health related policy, quality of health systems) on health outcomes (e.g. death, non-communicable disease development) across a range of socioeconomic and health resource settings. Additional components of this study will examine genetic factors for non-communicable diseases. This will be examined both through a cross sectional component, and prospectively (cohort component).",[152,206,207,208,209,28,210,29,211],"Risk Factor, Cardiovascular","Health Behavior","Environmental Exposure","Lung Diseases","Injuries","Communicable Disease",[213],"Non-communicable Diseases, Risk Factors","2024-01-29",{"date":216,"type":35},"2024-01-31",{"date":218,"type":35},"2002-01-01",{"date":220,"type":21},"2030-12-31",{"name":222,"class":78},"Population Health Research Institute",34,{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":232,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":234,"conditions":235,"keywords":243,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":5},"100525619","outcomes-of-children-after-hospitalization-in-intensive-care-unit-100525619","NCT06124092","Outcomes of Children After Hospitalization in Intensive Care Unit","After Pediatric Critical Illness (APCI)","APCI","Inclusion Criteria:\n\n* Children ≤18yo hospitalized in PICU for ≥96 hours\n\nExclusion Criteria:\n\n1. gestational age \\\u003C37 weeks or age \\>18 years at PICU entry;\n2. admitted for congenital heart surgery (followed in neuro-cardiac clinics in most centers);\n3. anticipated life expectancy \\\u003C1year (e.g., active do not resuscitate status).",{"count":233,"type":21},690,"More than 10,000 children are hospitalized in an PICU every year in Canada. While most of them will survive their PICU hospitalization and their critical illness, some children will not recover to their pre-illness level. Some may develop behavioral, physical, emotional or developmental problems and difficulties at school. All these problems are elements that are part of the Pediatric Post-Intensive Care Syndrome (PICS-p).\n\nIt is important to understand the elements (risk factors) that play a role in the development of PICS-p. In Canada, there is no systematic follow-up for children after they leave the PICU. Understanding what can cause PICS-p (risk factors) and how much PICS-p has an impact on children and their family is very important to the family well-being.",[29,236,237,238,239,240,241,242],"Liver Diseases","Heart Diseases","Trauma Injury","Sepsis","Septic Shock","Pneumonia","Bronchiolitis",[244,245],"Pediatric Intensive Care Unit","PICU","2023-11-03",{"date":248,"type":35},"2023-11-09",{"date":250,"type":21},"2024-03",{"date":252,"type":21},"2029-03",{"name":254,"class":78},"St. Justine's Hospital"]